title: Olea sublingual allergoid immunotherapy administered with two different treatment regimens.
abstract: Sublingual immunotherapy (SLIT) with monomeric carbamylated allergoid administered in accordance with the standard regimen has proven to be effective and safe. Achieving clinical benefit, however, requires a lengthy period of time so it is not very suitable for short-lasting allergies. We thus performed this study to compare an administration protocol starting in the coseasonal period (with a 4-day build-up phase) with a precoseasonal scheme to verify if the former regimen provides the same benefit in a shorter period of time. The prospective, randomized, drug therapy-controlled study was conducted in 33 rhinitic patients monosensitized to Olea with or without asthma. Ten patients were assigned to the coseasonal therapy with 5000 allergic units (AU)/week for 6 weeks, 11 to the precoseasonal therapy with 3000 AU/week for 10 weeks, and 12 to drug therapy. They were treated from April or May to June 2008. A visual analog scale (VAS) was performed at baseline and after treatment to assess the well being of the patients. Drug consumption was evaluated by means of a monthly diary. There was greater VAS improvement in both the SLIT groups versus the controls, but it was statistically significant only in the coseasonal group (p < 0.01). Furthermore, there was a reduction in the rescue medication only in the coseasonal SLIT (p < 0.05 versus drug therapy). One mild adverse event was observed. The allergoid SLIT was shown to be effective and safe in Olea allergy in particular when a coseasonal regimen was used.
authors.affiliation: Department of Pneumology, University, Catania, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Leonardi
authors.forename: Antonio
authors.initials: A
authors.lastname: Arena
authors.forename: Marco E
authors.initials: ME
authors.lastname: Bruno
authors.forename: Paola M
authors.initials: PM
authors.lastname: Cannaò
authors.forename: Roberto W
authors.initials: RW
authors.lastname: D'Anneo
authors.forename: Paolo
authors.initials: P
authors.lastname: Falagiani
authors.forename: Enrico
authors.initials: E
authors.lastname: Gammeri
authors.forename: Gianni
authors.initials: G
authors.lastname: Mistrello
authors.forename: Alessandra
authors.initials: A
authors.lastname: Nicolini
authors.forename: Luisa
authors.initials: L
authors.lastname: Ricciardi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Valenti
authors.forename: Rosaria
authors.initials: R
authors.lastname: Longo
authors.forename: Mario
authors.initials: M
authors.lastname: La Rosa
mesh_terms: D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D052179:Antigens, Plant / Q000008:administration & dosage* / Q000276:immunology; D001249:Asthma / Q000150:complications / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D002648:Child; D002985:Clinical Protocols; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D008297:Male; D031658:Olea / Q000276:immunology*; D011446:Prospective Studies; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D012621:Seasons
chemical_list: D052179:Antigens, Plant